# US 2016/0256389 A1 · Combination liposomal pharmaceutical formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256389 A1
- Document ID: US20160256389A1
- Status: Published application
- Kind: A1
- Application number: 15/059,972
- Filed: 2016-03-03
- Published: 2016-09-08
- Earliest claimed: 2015-03-03
- Assignees: Cureport, Inc.
- Applicants: Cureport, Inc.
- Inventors: De-Min Zhu; Guoqiang Chen
- Web page: https://patentgrep.com/patent/US20160256389A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/1278: Post-loading, e.g. by ion or pH gradient
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/6911: {the form being a liposome}
- A61P 35/02: specific for leukemia
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, DC-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel. The pharmaceutical composition can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer, preferably hepatocellular carcinoma (HCC).

## Claims

### Claim 1

A pharmaceutical composition comprising two types of liposomes:
(i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and
(ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior,
wherein the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first lipid layer, the second lipid layer, or both the first and second lipid layers consist essentially of the unsaturated phospholipid and cholesterol.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first lipid layer, the second lipid layer, or both the first and second lipid layers consist essentially of the unsaturated phospholipid, cholesterol, and a pegylated phospholipid.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein docetaxel is the only API in the first liposome type and/or doxorubicin is the only API in the second liposome type.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first lipid layer, the second lipid layer, or both the first and second lipid layers comprise:
about 20-75% (molar) unsaturated phospholipid;
about 10-60% (molar) cholesterol; and
about 0-20% (molar) pegylated phospholipid.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein:
the molar ratio of the first lipid layer components:docetaxel is about 100:1 to about 5:1; and
the molar ratio of the second lipid layer components:doxorubicin is about 100:1 to about 5:1.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the molar ratio of doxorubicin:docetaxel is about 10:1 to 1:10.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the unsaturated phospholipid comprises a polyunsaturated phospholipid or a monounsaturated phospholipid.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cholesterol comprises a cationic cholesterol derivative.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the composition is adapted to target one or more organs in a subject.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first liposome further comprises a pegylated phospholipid.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, formulated for intravenous administration.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the Z-average particle size of the liposomes is about 10-200 nm.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein, upon intravenous administration to a subject, at least about 10% of the composition is delivered to the liver.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method of treating a subject comprising administering an effective amount of the pharmaceutical composition of claim 1 to the subject, wherein the subject has a cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer is a lung cancer; colon cancer; breast cancer; stomach cancer; esophagus cancer; prostate cancer; leukemia; head and neck cancer; pancreatic cancer; multiple myeloma; or liver cancer.

### Claim 20 (depends on 1)

A method of making the pharmaceutical composition of claim 1, comprising:
(i) making a first liposome type by concurrently introducing a first lipid solution of an unsaturated phospholipid, a sterol, and docetaxel, in ethanol through a first or plural inlet ports into a mixing chamber of a manifold and introducing a first aqueous solution through a second or plural inlet ports into the mixing chamber of the manifold, and the liposomes exit the mixing chamber through one or plural outlet chambers of the manifold,
wherein the resulting first liposome type does not comprise doxorubicin;
(ii) making a second liposome type by concurrently introducing a second lipid solution in ethanol through a first or plural inlet ports into a mixing chamber of a manifold and introducing a first aqueous solution through a second or plural inlet ports into the mixing chamber of the manifold, and the liposomes exit the mixing chamber through one or plural outlet chambers of the manifold; and incubating the resulting liposomes with doxorubicin,
wherein the resulting second liposome type does not comprise docetaxel; and
(iii) combining predetermined amounts of the first liposome type and the second liposome type, thereby making the pharmaceutical composition of claim 1.

### Claim 21 (depends on 8)

The pharmaceutical composition of claim 8, wherein the unsaturated phospholipid comprises soy phosphatidylcholine or 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC).

### Claim 22 (depends on 9)

The pharmaceutical composition of claim 9, wherein the cholesterol comprises a dimethylaminoethanecarbamoyl-cholesterol (DC-cholesterol).

### Claim 23 (depends on 20)

The method of claim 20, wherein the first lipid solution further comprises a pegylated phospholipid.
